Trump announces trade deal with EU following months of negotiations
MINNEAPOLIS and BRISBANE, Australia - Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a structural heart company with a market capitalization of $168 million, has announced that its DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients suffering from severe aortic stenosis. According to InvestingPro analysis, the company appears undervalued despite its stock trading near 52-week lows. This milestone underscores the company’s commitment to advancing cardiac care.
The DurAVR® THV, which is designed to mimic the natural function of the human aortic valve, has been used in a variety of cases, including first-time aortic stenosis patients, valve-in-valve procedures, and in those with complex anatomies like bicuspid aortic valve conditions.
Of the treated patients, 65 have completed the primary endpoint measures of safety and efficacy, showing hemodynamic benefit at 30-days post-implant. Additionally, one-year efficacy data on 37 patients has demonstrated sustained hemodynamic performance, with large effective orifice areas and low mean pressure gradients, indicating an excellent safety profile with no valve or cardiovascular related mortality. While clinical results are promising, InvestingPro data shows the company maintains a healthy current ratio of 4.51, with cash reserves exceeding debt obligations, providing financial flexibility for continued development.
Chris Meduri, M.D., Chief Medical Officer at Anteris, expressed pride in reaching this clinical milestone, highlighting the potential of DurAVR® to redefine successful treatment outcomes in aortic stenosis. Dr. Michael Reardon, the Study Chair of the DurAVR® THV Pivotal Trial, emphasized the importance of building on clinical evidence and the upcoming all-risk, head-to-head DurAVR® registration trial.
Wayne Paterson, Vice Chairman and CEO, pointed out the clinical and commercial significance of the milestone, noting the differentiated results achieved with DurAVR®. The company anticipates beginning the DurAVR® THV Pivotal Trial in the third quarter of 2025, pending FDA approval.
Anteris Technologies, with a significant presence in both Australia and Minneapolis, USA, has been at the forefront of developing medical devices for structural heart disease. The DurAVR® THV is part of their suite of solutions that includes the ADAPT® anti-calcification tissue technology, FDA-cleared and used in over 55,000 patients globally.
The information in this article is based on a press release statement from Anteris Technologies Global Corp. With the next earnings report expected on May 28, 2025, investors can access additional insights and 8 more exclusive ProTips through InvestingPro, including detailed analysis of the company’s financial health and growth prospects.
In other recent news, Anteris Technologies Global Corp. has reported its annual financial results for the fiscal year ending December 31, 2024. While specific financial figures were not disclosed, the company has demonstrated compliance with regulatory standards by releasing audited financial information through the Australian Securities Exchange. Anteris Technologies also achieved a clinical milestone with its DurAVR® Transcatheter Heart Valve, having successfully treated 100 patients, marking a significant step in its clinical applications. Additionally, the company announced favorable one-year patient outcomes for the DurAVR® THV, highlighting improvements in valve function and heart health. In terms of market activities, Anteris Technologies exercised a partial over-allotment option from its initial public offering, signaling a positive market reception. Analyst firm Cantor Fitzgerald initiated coverage of Anteris with an Overweight rating, citing confidence in the company’s DurAVR technology and its potential market impact. The firm’s analyst set a price target of $9.00, reflecting optimism about the company’s future growth in the transcatheter aortic valve replacement market. These developments collectively illustrate Anteris Technologies’ progress and strategic positioning in the medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.